This page is part of the FHIR Specification (v4.0.1: R4 - Mixed Normative and STU) in it's permanent home (it will always be available at this URL). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R4 R3
Vocabulary Work Group | Maturity Level: 1 | Draft | Use Context: Any |
This value set (http://terminology.hl7.org/ValueSet/v3-ActSubstanceAdminSubstitutionCode) is defined as part of HL7 v3.
Summary
Defining URL: | http://terminology.hl7.org/ValueSet/v3-ActSubstanceAdminSubstitutionCode |
Version: | 2014-03-26 |
Name: | v3.ActSubstanceAdminSubstitutionCode |
Title: | V3 Value SetActSubstanceAdminSubstitutionCode |
Definition: | No Description Provided |
OID: | 2.16.840.1.113883.1.11.16621 (for OID based terminology systems) |
Source Resource | XML / JSON |
This value set is used in the following places:
This value set includes codes from the following code systems:
http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution
where concept is-a _ActSubstanceAdminSubstitutionCodehttp://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution
Code | Display | |
_ActSubstanceAdminSubstitutionCode | ActSubstanceAdminSubstitutionCode | Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects. |
This expansion generated 01 Nov 2019
This value set contains 9 concepts
Expansion based on http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution version 2018-08-12
All codes from system http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution
Code | Display | Definition |
E | equivalent | Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product. |
EC | equivalent composition | Description: Substitution occurred or is permitted with another product that is a: pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration Examples: Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate Pharmaceutical equivalent: Lisonpril for Zestril |
BC | brand composition | Description: Substitution occurred or is permitted between equivalent Brands but not Generics Examples: Zestril for Prinivil Coumadin for Jantoven |
G | generic composition | Description: Substitution occurred or is permitted between equivalent Generics but not Brands Examples: Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp) |
TE | therapeutic alternative | Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile. Examples: ranitidine for Tagamet |
TB | therapeutic brand | Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics > Examples: Zantac for Tagamet |
TG | therapeutic generic | Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands > Examples: Ranitidine for cimetidine |
F | formulary | Description: This substitution was performed or is permitted based on formulary guidelines. |
N | none | No substitution occurred or is permitted. |